AGOURA HILLS, Calif., Sept. 2, 2016 /PRNewswire-iReach/ -- Oncotelic Inc. researchers will conduct two presentations titled (i) 'Cytokine Induction by Trabedersen (OT-101) Treatment - Results from a Phase I/II Trial in Pancreatic Cancer Patients' on September 4th, 2016 at the 43rd International Society of Oncology and Biomarkers (ISOBM) Congress in Chicago, IL and (ii) 'Impact of Antisense OT-101 Therapy on the Cytokine and Chemokine Profile in Patients with Pancreatic Cancer' on September 26, 2016 at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal, Canada.
Photo - http://photos.prnewswire.com/prnh/20160901/403439
Oncotelic is developing TGF- 2 antisense as immunotherapy against pancreatic, melanoma, and glioblastoma. IL-8 spike was predictive of TGF 2 immunotherapy probably due to its potentiation of the cytokine storm during immunotherapy. IL-8 spike during 1st cycle of therapy is associated with improved overall survival in pancreatic cancer patients treated with Trabedersen/OT-101 - above and beyond those seen with current treatments.
The presentations will be as follows:
Title : Cytokine Induction by Trabedersen (OT-101) Treatment - Results from a Phase I/II Trial in Pancreatic Cancer Patients
Conference : The 43rd International Society of Oncology and Biomarkers (ISOBM) Annual Congress, Sept. 1-6, 2016, Chicago, IL
Time and Date : Sunday September 4th 10:50am - 11:00am (Oral Presentation)
Authors : Vuong Trieu1, Sanjive Qazi2, Kevin Ng2, Osmond D'Cruz2, Joyce Lin2, Larn Hwang1
Institutions : 1Oncotelic Inc., Agoura Hills, CA 91301; 2Autotelic Inc., Costa Mesa, CA 92626
Contact : info@oncotelic.com
Title : Impact of Antisense OT-101 Therapy on the Cytokine and Chemokine Profile in Patients with Pancreatic Cancer
Conference : The 12th Annual Meeting of the Oligonucleotide Therapeutics Society Sept. 25-28, 2016, Montreal, Canada
Time and Date : Monday, September 26th 5:00pm - 7:30pm
Authors : Larn Hwang 1, Osmond D'Cruz2, Kevin Ng2, Sanjive Qazi2, Vuong Trieu1
Institutions : 1Oncotelic Inc., Agoura Hills, CA 91301; 2Autotelic Inc., Costa Mesa, CA 92626
Contact : info@oncotelic.com
More information is available at www.oncotelic.com and www.autotelicinc.com.
About Trabedersen
Trabedersen, (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) designed to specifically target the human TGF-2 messenger RNA. The Mechanism of Action exploration focuses on target downregulation and immunostimulation. Trabedersen is believed to reverse TGF-'s immunosuppressive effects, rendering the tumor visible to a patient's immune system and resulting in priming and specific activation of the patient's anti-tumor immune response. OT-101 has completed multiple clinical trials and is poised to for multiple phase II combination trial followed by pivotal phase III registration trials.
About Oncotelic Inc.
Oncotelic's lead therapeutic platform is OT-101 (Trabedersen). Oncotelic intends to conduct registration trials for multiple cancer indications including pancreatic, melanoma, and glioblastoma. The executives of Oncotelic are a group of pharmaceutical veterans who believe that Trabedersen will present a paradigm shift in the treatment of cancers.
About Autotelic Inc.
Autotelic works through partners to transform how medications are being delivered. The Autotelic Inc. platform is aTherapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. Current dosing schemes result in either too much drug exposure or too little drug exposure because of individual pharmacokinetic variations. The Autotelic pipeline includes TDM devices for management of oncology, hypertension and pain.
Forward-Looking Statements
This press release contains forward-looking statements which are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the Trabedersen; and the clinical development and commercial potential of Trabedersen. All such forward-looking statements are based on Oncotelic's current beliefs and expectations, and should not be regarded as a representation by Oncotelic that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Oncotelic's businesses, including: the company may require substantial additional funding in order to obtain regulatory approval for and commercialize any products; the risk that delays in the regulatory approval or commercial launch of Trabedersen will enable competitors to develop and bring new competing products to market before the approval, if any, of Trabedersen; the scope and validity of patent protection for Trabedersen as well as Oncotelic's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; and additional risks set forth in any of Oncotelic's public announcements. These forward-looking statements represent Oncotelic's judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Oncotelic undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Media Contact: Larn Hwang Ph.D. Cheif Executive Officer, Oncotelic Inc., 818-575-9505, info@oncotelic.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Oncotelic Inc.
